BeOne Medicines Ltd
228 hedge funds and large institutions have $10.4B invested in BeOne Medicines Ltd in 2024 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 52 increasing their positions, 88 reducing their positions, and 25 closing their positions.
142% more call options, than puts
Call options by funds: $66.1M | Put options by funds: $27.3M
116% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 25
56% more capital invested
Capital invested by funds: $6.68B → $10.4B (+$3.76B)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
14% more funds holding
Funds holding: 200 → 228 (+28)
0.02% less ownership
Funds ownership: 3.75% → 3.73% (-0.02%)
41% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$76.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$51.4M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$36M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$29.3M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$113M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$105M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$49.9M |
| 4 |
AG
Artal Group
Luxembourg
|
-$43.3M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$41.4M |
ONC Hedge Fund Activity: Q3 2024 in Review
228 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2024, worth a combined $10.4B — up 56% from $6.68B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ONC positions and 25 closed out — a net gain of 29 holders — while 52 added to existing stakes and 88 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $76.9M. The largest seller was Temasek Holdings, cutting an estimated $113M.
- 228 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2024, up from 200 in Q2 2024.
- Funds reported $10.4B of BeOne Medicines Ltd stock for Q3 2024, up 56% quarter-over-quarter.
- 54 funds opened new BeOne Medicines Ltd positions in Q3 2024 and 25 closed out, a net change of +29 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2024 was T. Rowe Price Associates, an estimated $76.9M added.
- The largest BeOne Medicines Ltd seller in Q3 2024 was Temasek Holdings, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2024.